Product and service revenue of €3.2 million, up 37% driven by strong CellTolerance® momentum in Europe and new international markets
Gross margin on product and service revenue of 65%, up 2 points
Operating expenses1 of €5.9 million, with R&D and G&A slightly down
Financial visibility extended to the end of 2027 with the renewed support of long-term shareholder and partner Vester Finance
Paris and Boston, October 8th, 2026 – 7:00 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reports its consolidated results for the first half of 2026, as approved by the Board of Directors on September 28, 2026. The half-year financial report will be available on the Company’s website.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “The first half of 2026 was consistent with our roadmap. Growth was driven by CellTolerance®, with dynamic sales in Europe, notably in Germany and Switzerland, and first sales in new markets such as the United Arab Emirates, Australia and Spain, while we maintained strict cost discipline. In the United States, we have evolved our commercial model with a dedicated Clinical Associates team focused on providing clinical support and driving Cellvizio usage. Completed in June, this organization is ramping up and lays the foundations for healthy, sustainable growth.
At the same time, the clinical foundations of Cellvizio continue to strengthen, with results confirmed both in Barrett’s esophagus, through the large independent meta-analysis conducted in South Korea, and in pancreatic cysts, with the CLIMB study and associated ancillary studies. Cellvizio is becoming established in interventional endoscopy. Finally, thanks to the renewed commitment of our long-term shareholder and partner, Vester Finance, our financial visibility now extends to the end of 2027, giving us the means to execute our plan.”
1 Excluding share-based payments
